TARDBP and Cognitive impairment: Interestingly, Patient #3, who carried the Q23L variant, developed moderate cognitive impairment over the extended course of his illness, with end-stage clinical features consistent with frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP).